Cannabis: The Effects on Patients With Respiratory Conditions

Price: FREE for members and non-members

Session recorded on May 21, 2020
Speaker: William Silvers, MD
Viewers can earn credit by completing the posttest questions

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

There is no commercial support for this activity.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Target Audience

Primary Care Providers
Fellows-in-Training
 

Learning Objectives

Upon completion of this podcast, the participant should be able to:

  1. Describe the spectrum and prevalence of allergic reactions to Cannabis (“Marijuana”)
  2. Discuss better communication, non-judgmental, between patients and physicians
  3. Update on diagnosis, management, and benefits/harms of cannabis
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.


 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
05/21/2020
Course expires: 
10/31/2025
Rating: 
0

All identified conflicts of interest have been resolved.

Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose

Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

William Silvers, MD, Speaker
Nothing to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.